

## Representative Life Sciences Deals

- Over \$6.9 Billion in Commitments to more than 380 Companies since 2003
- Total New Debt & Equity Commitments of ~\$397.0 Million YTD
- Total New Fundings of ~\$340.6 Million YTD
- Over 1,000 Co-investments with Different VC & PE Firms in the Last 13 Years
- Over 130 Companies completed IPO or M&A Events since Inception




**\$30,000,000  
Debt Commitment**

Invested in 2011, 2013, 2015, 2017  
NASDAQ: ACRX




**\$35,000,000  
Debt Commitment**

Invested in 2017



**\$20,000,000  
Debt Commitment**

Invested in 2017  
NASDAQ: BOLD



**\$55,000,000  
Debt Commitment**

Invested in 2017  
NASDAQ: AXON



**\$30,000,000  
Debt Commitment**

Invested in 2016, 2017  
NASDAQ: BLCM



**\$15,000,000  
Debt Commitment**  
**\$1,000,000  
Equity Commitment**

Invested in 2014, 2015, 2016, 2017



**\$45,000,000  
Debt Commitment**

Invested in 2014, 2015, 2016  
NASDAQ: ALIM



**\$20,000,000  
Debt Commitment**  
**\$1,000,000  
Equity Commitment**

Invested in 2014, 2015, 2016  
NASDAQ: EDGE



**\$55,000,000  
Debt Commitment**  
**\$1,000,000  
Equity Commitment**

Invested in 2012, 2014, 2016  
NASDAQ: INSM



**\$60,000,000  
Debt Commitment**

Invested in 2016  
NASDAQ: SRNE



**\$15,000,000  
Debt Commitment**

Invested in 2014, 2015  
Acquired by Jazz Pharma in 2016



**\$45,000,000  
Debt Commitment**

Invested in 2013  
Acquired by Pfizer in 2016

**CoNCERT**  
Pharmaceuticals Inc.®

\$30,000,000  
**Current Debt Commitment**  
\$20,000,000  
**Prior Debt Commitment**

Invested in 2011, 2012, 2017  
NASDAQ: CNCE

 **PARATEK**™

\$60,000,000  
**Debt Commitment**  
\$1,000,000  
**Equity Commitment**

Invested in 2014, 2015, 2016, 2017  
NASDAQ: PRTK

  
Quanta

\$27,500,000  
**Debt Commitment**

Invested in 2016

**DYNAVAX**  
INNOVATING IMMUNOLOGY

\$40,000,000  
**Debt Commitment**  
\$550,000  
**Equity Commitment**

Invested in 2014, 2015  
NASDAQ: DVAX

 **Medrobotics**  
Expanding the reach of surgery®

\$15,000,000  
**Debt Commitment**  
\$905,000  
**Equity Commitment**

Invested in 2013, 2014, 2015

  
**Melinta**  
THERAPEUTICS  
The Antibiotics Company

\$30,000,000  
**Debt Commitment**  
\$2,000,000  
**Equity Commitment**

Invested in 2014, 2015

  
**MERRIMACK**  
PHARMACEUTICALS

\$25,000,000  
**Current Debt Commitment**  
\$55,000,000  
**Prior Debt Commitment**

Invested in 2005, 2007, 2012, 2015  
NASDAQ: MACK

  
**NEOS**  
Therapeutics

\$25,000,000  
**Debt Commitment**  
\$1,500,000  
**Equity Commitment**

Invested in 2014, 2015  
NASDAQ: NEOS

  
**Outset**

\$15,500,000  
**Debt Commitment**  
\$500,000  
**Equity Commitment**

Invested in 2013, 2014, 2015

 **TransMedics**

\$8,500,000  
**Debt Commitment**  
\$2,500,000  
**Equity Commitment**

Invested in 2008, 2010, 2012, 2015

  
**uniQure**

\$20,000,000  
**Debt Commitment**

Invested in 2013, 2014  
NASDAQ: QURE

  
**revance**®

\$22,000,000  
**Debt Commitment**

Invested in 2011  
NASDAQ: RVNC

**Boston Office**

**R. Bryan Jadot**  
Sr. Managing Director  
617.314.9981  
bjadot@htgc.com

**Kristen Kosofsky**  
Sr. Managing Director  
617.851.5416  
kkosofsky@htgc.com

**Janice Bourque**  
Managing Director  
617.314.9992  
jbouque@htgc.com

**Palo Alto Office**

**Himani Bhalla**  
Principal  
650.433.5581  
hbhalla@htgc.com

**Jeffrey Becker**  
Vice President  
650.433.5595  
jbecker@htgc.com

**New York Office**

**Anup Arora**  
Managing Director  
212.774.3612  
aarora@htgc.com

**San Diego Office**

**Lake McGuire**  
Managing Director  
517.304.0382  
lmcguire@htgc.com